Science Explorer Back to mapMap
Discussion
Company · Kobe · Japan

Eli Lilly (Japan)

In research, Eli Lilly (Japan) stands highest in Health Sciences (#9,643 of 16,688 worldwide) and Medicine (#9,029 of 14,558 worldwide), over all time.

lilly.co.jpROR OpenAlex
World rank, all time
#29,013
of 34,923
Rank in Japan
#1,230
of 1,923
Research works
237
▼ 10% vs 2018-21
Citations
3.7k
15.7 per fractional work
Top-10% rate
10.8%
all institutions 10.0%
vs its own fields
0.95×
1.00× is exactly expected
Open access
65%
world 40%
International
41%
world 18%
Eli Lilly (Japan)

What is Eli Lilly (Japan) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Health SciencesDomain #9,643 of 16,688 9.1%181
MedicineField #9,029 of 14,558 9.1%176

Each strip is that field's whole ranked pool, with the notch where Eli Lilly (Japan) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Eli Lilly (Japan) work in?

In 2022-now, 84% of research at Eli Lilly (Japan) is in Health Sciences, 11% in Life Sciences. Its largest fields are Medicine (82%), Biochemistry, Genetics and Molecular Biology (5%), Immunology and Microbiology (2%). It does 3.2× the world's share of Health Sciences.

Health Sciences: 48 fractional works · 84.2% of its workMedicine: 47 fractional works · 82.2% of its workEndocrinology, Diabetes and Metabolism: 12 fractional works · 20.1% of its workOncology: 6 fractional works · 9.8% of its workPsychiatry and Mental health: 5 fractional works · 9.2% of its workPulmonary and Respiratory Medicine: 5 fractional works · 7.8% of its workRheumatology: 3 fractional works · 4.7% of its workPhysiology: 3 fractional works · 4.5% of its workSurgery: 2 fractional works · 3.9% of its workEpidemiology: 2 fractional works · 2.9% of its workDermatology: 2 fractional works · 2.8% of its workPathology and Forensic Medicine: 1 fractional works · 1.8% of its workImmunology and Allergy: 1 fractional works · 1.7% of its workPharmacology: 1 fractional works · 1.6% of its workGenetics: 1 fractional works · 1.6% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 1.3% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 1.2% of its workHepatology: 1 fractional works · 1.2% of its workFamily Practice: 1 fractional works · 1.1% of its workNeurology: 1 fractional works · 0.9% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 0.9% of its workHematology: 0 fractional works · 0.6% of its workUrology: 0 fractional works · 0.6% of its workAnesthesiology and Pain Medicine: 0 fractional works · 0.6% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.3% of its workGastroenterology: 0 fractional works · 0.2% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.2% of its workRehabilitation: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.4% of its workHealth Professions: 1 fractional works · 1.8% of its workGeneral Health Professions: 1 fractional works · 1.4% of its workPharmacy: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workNursing: 0 fractional works · 0.1% of its workLife Sciences: 6 fractional works · 10.5% of its workBiochemistry, Genetics and Molecular Biology: 3 fractional works · 5.1% of its workCancer Research: 1 fractional works · 2.3% of its workGenetics: 1 fractional works · 1.4% of its workMolecular Biology: 1 fractional works · 1.2% of its workCell Biology: 0 fractional works · 0.3% of its workImmunology and Microbiology: 1 fractional works · 2.4% of its workImmunology: 1 fractional works · 2.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNeuroscience: 1 fractional works · 2.2% of its workNeurology: 1 fractional works · 1.4% of its workCognitive Neuroscience: 0 fractional works · 0.3% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.8% of its workPharmacology: 0 fractional works · 0.8% of its workSmaller subfields together: 0 fractional works · 0.1% of its workSocial Sciences: 3 fractional works · 4.5% of its workEconomics, Econometrics and Finance: 1 fractional works · 2.0% of its workEconomics and Econometrics: 1 fractional works · 2.0% of its workPsychology: 1 fractional works · 1.9% of its workClinical Psychology: 1 fractional works · 1.6% of its workApplied Psychology: 0 fractional works · 0.3% of its workSocial Sciences: 0 fractional works · 0.6% of its workHealth: 0 fractional works · 0.6% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPhysical Sciences: 0 fractional works · 0.8% of its workMathematics: 0 fractional works · 0.6% of its workStatistics and Probability: 0 fractional works · 0.6% of its workComputer Science: 0 fractional works · 0.2% of its workChemistry: 0 fractional works · 0.0% of its workALL ITS WORKEli Lilly (Japan)58fractional works, 2022-now
Life Sciences11%Physical Sciences1%Health Sciences84%Social Sciences4%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 13 fields, with their numbers
    1. Medicine4782.2%
    2. Health Professions11.8%
    3. Nursing00.1%
    1. Biochemistry, Genetics and Molecular Biology35.1%
    2. Immunology and Microbiology12.4%
    3. Neuroscience12.2%
    4. Pharmacology, Toxicology and Pharmaceutics00.8%
    1. Economics, Econometrics and Finance12.0%
    2. Psychology11.9%
    3. Social Sciences00.6%
    1. Mathematics00.6%
    2. Computer Science00.2%
    3. Chemistry00.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 0.96× its world share, 3 worksBiochemistry, Geneti…Immunology and Microbiology: 2.35× its world share, 1 worksImmunology and Micro…Neuroscience: 1.36× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.37× its world share, 0 worksPharmacology, Toxico…Chemistry: 0.02× its world share, 0 worksChemistryComputer Science: 0.03× its world share, 0 worksComputer ScienceMathematics: 0.48× its world share, 0 worksMathematicsHealth Professions: 0.70× its world share, 1 worksHealth ProfessionsMedicine: 4.28× its world share, 47 worksMedicineNursing: 0.17× its world share, 0 worksNursingEconomics, Econometrics and Finance: 0.92× its world share, 1 worksEconomics, Econometr…Psychology: 0.62× its world share, 1 worksPsychologySocial Sciences: 0.05× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.3×. Every wedge is a field page.

All 13 fields, with their numbers
  1. Medicine4.28×47 works
  2. Pharmacology, Toxicology and Pharmaceutics2.37×0 works
  3. Immunology and Microbiology2.35×1 works
  4. Neuroscience1.36×1 works
  5. Biochemistry, Genetics and Molecular Biology0.96×3 works
  6. Economics, Econometrics and Finance0.92×1 works
  7. Health Professions0.70×1 works
  8. Psychology0.62×1 works
  9. Mathematics0.48×0 works
  10. Nursing0.17×0 works
  11. Social Sciences0.05×0 works
  12. Computer Science0.03×0 works
  13. Chemistry0.02×0 works

Who are the top researchers at Eli Lilly (Japan)?

Ranked on the quality score, Tomonori Oura, Mika Komori and Kaname Ueda lead among researchers whose main affiliation is Eli Lilly (Japan).

  1. 1 Tomonori Oura Japan · #559,663 worldwide 1.5k citations · 59 works
  2. 2 Mika Komori Japan · #727,744 worldwide 2.1k citations · 75 works
  3. 3 Kaname Ueda Japan · #1,224,569 worldwide 1k citations · 36 works
  4. 4 Yoshinori Tanizawa Japan · #1,370,750 worldwide 1.1k citations · 70 works
  5. 5 Yongzhe Piao Japan · #1,484,163 worldwide 1.1k citations · 66 works
  6. 6 Takeshi Imaoka Japan · #1,537,588 worldwide 1.4k citations · 80 works
  7. 7 Tomotaka Shingaki Japan · #1,669,603 worldwide 154 citations · 20 works
  8. 8 Yoji Morisaki Japan · #1,809,219 worldwide 775 citations · 20 works
  9. 9 Masakazu Takeuchi Japan · #2,425,877 worldwide 762 citations · 39 works
  10. 10 Akichika Ozeki Japan · #2,642,977 worldwide 472 citations · 31 works
All ranked researchers at Eli Lilly (Japan)

What are the most cited papers from Eli Lilly (Japan)?

The most cited paper from Eli Lilly (Japan) is "Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan" (Takuji Okusaka, Kohei Nakachi, Akira Fukutomi et al., 2010), with 757 citations. Next come "Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial" (619) and "Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor" (373).

Most cited papers
#PaperReleasedCitations
1 Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan Takuji Okusaka, Kohei Nakachi, Akira Fukutomi et al. · British Journal of Cancer Open access 13 Jul 2010 757
2 Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa et al. · The Lancet Oncology Open access131 authors 4 Oct 2019 619
3 Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor Patrick C. May et al. · Journal of Neuroscience Open access 16 Nov 2011 373
4 Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment Josef S Smolen, Mark C. Genovese, Tsutomu Takeuchi et al. · The Journal of Rheumatology Open access 15 Sep 2018 260
5 Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura et al. · The Lancet Diabetes & Endocrinology Open access 30 Jul 2022 226
All 60 most cited papers, with filters and sorting

Which keywords describe research at Eli Lilly (Japan)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Glycemic Control, Insulin Therapy, Diabetes, Cardiovascular Disease, Type 2 Diabetes, Obesity, Heart Failure and Clinical Guidelines.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Glycemic Control9▲ 98×4 topics
  2. Insulin Therapy9▲ 119×3 topics
  3. Diabetes7▲ 24×5 topics
  4. Cardiovascular Disease6▲ 9.1×10 topics
  5. Type 2 Diabetes5▲ 41×3 topics
  6. Obesity5▲ 11×10 topics
  7. Heart Failure4▲ 17×3 topics
  8. Clinical Guidelines4▲ 25×3 topics
  9. Cardiovascular Outcomes4▲ 120×1 topic
  10. Glucose Control4▲ 120×1 topic
  11. Lifestyle Intervention4▲ 69×2 topics
  12. Chemotherapy4▲ 8.5×7 topics
  13. Type 1 Diabetes4▲ 72×2 topics
  14. Neurological Disorders3▲ 10×6 topics
  15. Cardiovascular Risk3▲ 18×4 topics
  16. Inflammation3▲ 2.7×13 topics
  17. Quality of Life3▲ 3.9×10 topics
  18. Metabolic Syndrome3▲ 6.6×7 topics
  19. Complications3▲ 11×2 topics
  20. Continuous Glucose Monitoring3▲ 113×1 topic
  21. Hypoglycemia3▲ 113×1 topic
  22. Breast Cancer3▲ 20×5 topics
  23. Metastatic Breast Cancer3▲ 80×2 topics
  24. Clinical Trials3▲ 6.8×9 topics
  25. Calcitonin Gene-Related Peptide2▲ 102×2 topics
  26. Clinical Practice Guidelines2▲ 7.8×6 topics
  27. Atherosclerosis2▲ 15×4 topics
  28. Headache Disorders2▲ 172×1 topic
  29. Insulin Resistance2▲ 9.2×3 topics
  30. Migraine2▲ 100×1 topic
  31. Cholesterol2▲ 27×2 topics
  32. Global Prevalence2▲ 39×1 topic
  33. Glucose Metabolism2▲ 39×1 topic
  34. Weight Loss2▲ 24×3 topics
  35. Encephalopathy2▲ 53×2 topics
  36. Health Outcomes2▲ 13×3 topics
  37. Critical Care2▲ 15×3 topics
  38. CDK4/6 Inhibitors2▲ 117×1 topic
  39. Diabetes Mellitus2▲ 16×3 topics
  40. Palbociclib2▲ 117×1 topic

Which research topics does Eli Lilly (Japan) publish most on?

By volume in 2022-now: Diabetes Treatment and Management, Diabetes Management and Research, Migraine and Headache Studies and Diabetes, Cardiovascular Risks, and Lipoproteins.

Diabetes Treatment and Management: 4 fractional worksDiabetes Management and Research: 3 fractional worksMigraine and Headache St…2Migraine and Headache Studies: 2 fractional worksDiabetes, Cardiovascular…2Diabetes, Cardiovascular Risks, and Lipoproteins: 2 fractional worksAdvanced Breast Cancer Therapies: 2 fractional worksNeurological Complications and Syndromes: 2 fractional worksHyperglycemia and glycem…2Hyperglycemia and glycemic control in critically ill and hospitalized patients: 2 fractional worksRheumatoid Arthritis Research and Therapies: 2 fractional worksDermatology and Skin Diseases: 1 fractional worksBariatric Surgery and Outcomes: 1 fractional works
Endocrinology, Diabetes and MetabolismPsychiatry and Mental healthPulmonary and Respiratory MedicineRheumatology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 4 works
  2. 2 Diabetes Management and Research Endocrinology, Diabetes and Metabolism 3 works
  3. 3 Migraine and Headache Studies Psychiatry and Mental health 2 works
  4. 4 Diabetes, Cardiovascular Risks, and Lipoproteins Endocrinology, Diabetes and Metabolism 2 works
  5. 5 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
  6. 6 Neurological Complications and Syndromes Psychiatry and Mental health 2 works
  7. 7 Hyperglycemia and glycemic control in critically ill and hospitalized patients Endocrinology, Diabetes and Metabolism 2 works
  8. 8 Rheumatoid Arthritis Research and Therapies Rheumatology 2 works
  9. 9 Dermatology and Skin Diseases Dermatology 1 works
  10. 10 Bariatric Surgery and Outcomes Surgery 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available64.9%not open35.1%

World: 40% of research is openly available.

with international co-authors40.7%domestic only59.3%

World: 18% is written across borders.

How has Eli Lilly (Japan)'s research output changed?

Output in 2022-2025 was 10% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Eli Lilly (Japan) as a percentage of every work published that year, 0.00021% in 2024.

still counting0.00020%0.00040%0.00060%Eli Lilly (Japan)0.00020% in 202519801990200020102020

Fractional works of Eli Lilly (Japan) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Kobe

All research institutions in Kobe

Share Eli Lilly (Japan)'s ranking

Eli Lilly (Japan) on Science Explorer

A card with Eli Lilly (Japan)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Eli Lilly (Japan). Posts are plain text and can be reported.